Video Experimental Relacionado
Updated: Sep 10, 2025
07:39
SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
Published on: June 28, 2019
24.2K
Apuntar a la senescencia en la oncología: una vía terapéutica emergente para el cáncer
Satoru Meguro1, Syunta Makabe1, Kei Yaginuma1
1Department of Urology, School of Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.
Current oncology (Toronto, Ont.)
|August 27, 2025
Resumen
La senescencia celular, un proceso relacionado con el envejecimiento, juega un doble papel en el cáncer. Dirigirse a las células senescentes con senoterápicos, especialmente combinados con terapia que induce la senescencia, es prometedor para futuros tratamientos contra el cáncer.
Área de la Ciencia:
- En el campo de la oncología
- Biología celular
- Gerontología
Sus antecedentes:
- La senescencia celular está estrechamente relacionada con el envejecimiento y el desarrollo del cáncer.
- La senescencia puede actuar como supresor tumoral al detener la proliferación, pero también promover el cáncer a través de factores secretados y superficies celulares alteradas.
- Las células senescentes en el microambiente tumoral, incluidos los fibroblastos, las células endoteliales y las células inmunes, pueden impulsar la progresión del cáncer.
Objetivo del estudio:
- Para explorar el papel multifacético de la senescencia celular en el cáncer.
- Revisar el impacto de la senescencia inducida por la terapia en los resultados del cáncer.
- Discutir el potencial de los senoterapéuticos como una nueva estrategia de tratamiento del cáncer.
Principales métodos:
- Revisión de la literatura de los estudios sobre la senescencia celular en el cáncer.
- Análisis del doble papel de la senescencia en la supresión y promoción de tumores.
- Examen de los senoterapéuticos y su combinación con terapias que inducen la senescencia.
Principales resultados:
- La senescencia exhibe efectos paradójicos, inhibiendo la proliferación y promoviendo potencialmente el crecimiento tumoral a través de la señalización paracrina y los cambios en el proteoma superficial.
- La senescencia inducida por la terapia puede influir en la eficacia y los resultados del tratamiento del cáncer.
- La senoterapia está emergiendo como una vía terapéutica prometedora, con ensayos clínicos en curso.
Conclusiones:
- La senescencia celular es un factor crítico en la biología del cáncer con implicaciones complejas.
- La senoterapia, especialmente cuando se combina con estrategias de inducción de la senescencia, representa un enfoque terapéutico en desarrollo para el cáncer.
- Se necesita más investigación para optimizar las aplicaciones senoterapéuticas en oncología clínica.
Videos de Conceptos Relacionados
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:15Replicative Cell Senescence
3.7K
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
3.7K
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K